Synergy Pharmaceuticals to Present at the Deutsche Bank Health Care Conference

NEW YORK–(BUSINESS WIRE)– Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company
is scheduled to present a corporate update at the 41^st Annual
Deutsche Bank Health Care Conference on Wednesday, May 4, 2016
at 2:50 p.m. Eastern Time.

A live webcast of the presentation will be accessible through the
Investor Relations section of the company’s website at www.synergypharma.com.
A replay of the webcast will be available on Synergy’s website for 60
days following the conference.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development and
commercialization of novel gastrointestinal (GI) therapies. Our
proprietary GI platform is based on uroguanylin and includes two lead
product candidates – plecanatide and dolcanatide. Plecanatide is our
first uroguanylin analog currently being evaluated for use as a
once-daily tablet for two functional GI disorders, chronic idiopathic
constipation and irritable bowel syndrome with constipation. Plecanatide
is a 16-amino acid peptide that is structurally similar to uroguanylin
with the exception of a single amino acid change. Plecanatide is
designed to replicate the function of uroguanylin by working locally in
the upper GI tract to stimulate digestive fluid movement and support
regular bowel function. Dolcanatide is our second uroguanylin analog
currently being explored for inflammatory bowel disease. Dolcanatide is
designed to be an analog of uroguanylin with enhanced resistance to
standard digestive breakdown by proteases in the intestine. For more
information, please visit www.synergypharma.com.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160426005423/en/